Veradermics Incorporated (MANE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Veradermics Incorporated (MANE) is Neutral.

The composite score behind that read is -0.15, weighing +0.41 of bullish evidence against -0.35 bearish.

Veradermics Incorporated last closed at $118.87, +1.81% on the session.

Against the IVW growth benchmark the position is +0.89% over the forecast window.

The read is built from 13 underlying insights — 4 bullish and 9 bearish.

Agreement across those insights is 69%.

16 graded predictions for MANE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Veradermics Incorporated in the 21st percentile on return on equity, where 100 is best.

Veradermics Incorporated is classified under Health Care / Pharmaceuticals, with a market capitalisation of $4.88B.

StockMap tracks Veradermics Incorporated as the 24th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Veradermics Incorporated ranks 51st of 128 in the group, against a group median of -0.24.